Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2025 08:30 ET | Source: Moleculin Biotech, Inc.

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

– Initial data readout on track for second half of 2025 HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage...